CLSA analysts upgraded Aurobindo Pharma (NSE:ARBN) (ARBP:IN) stock rating from Hold to Outperform, despite reducing the price target to INR1,400 from INR1,540. The revision reflects a modified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback